IRLAB Therapeutics AB (publ) announced that the company has secured top expertise in supporting the preparations for Phase III with mesdopetam. The collaboration starts immediately with Clintrex leading IRLAB's US regulatory strategy, and ProPharma Group acting as IRLAB's regulatory US agent. The first milestone is the preparation of a briefing package to be able to request an end-of-Phase 2 meeting with the US Food & Drug Administration (FDA), in which the Phase III program of mesdopetam will be defined.

Clintrex is a clinical research company that works with pharmaceutical organizations to operationalize development pathways for new treatments for central nervous system (CNS) diseases. Its team members are internationally renowned leaders in the global scientific and neurological communities and have extensive experience in all aspects of the development process for new drugs, devices, and biologics. Clintrex members have held important leadership and consulting positions in academic, pharmaceutical, and regulatory communities.